Disitamab Vedotin vs Tucatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT04311034 · Phase 1/2 · completed
The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.
Next expected readout: June 2027 · NCT06734182 (registry estimate)
No aligned efficacy figure on record for this race.
Tucatinib
Marketed by Pfizer and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2032 · NCT07768358 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Disitamab Vedotin | Tucatinib |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Disitamab Vedotin
- —Not reported
- Tucatinib
- —Not reported
OS, median
- Disitamab Vedotin
- —Not reported
- Tucatinib
- —Not reported
ORR
- Disitamab Vedotin
- —Not reported
- Tucatinib
- —Not reported
Duration of response, median
- Disitamab Vedotin
- —Not reported
- Tucatinib
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Disitamab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.
Tucatinib: registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT03500380 · Phase 2/3 · status unknown
This trial randomized 301 patients with HER2-positive metastatic breast cancer to disitamab vedotin or an active comparator regimen (lapatinib plus capecitabine), with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT07366840 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by an IRC (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months): Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). (met)
Result source: NCT03500380
Tucatinib
Marketed by Pfizer and partners
NCT03975647 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).
Next expected readout: December 2026 · NCT06016387 (registry estimate)
Reported efficacy
Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)
Result source: NCT05132582
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tucatinib
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Available safety results
Tucatinib
| Dropout rate | 34.6% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultn/a: no completion milestone NCT02614794 · Phase 2 · combination |
|---|---|
| Discontinued due to AEs | — NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result— NCT02614794 · Phase 2 · combination |
| Serious AEs | 30.3% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result30.7% NCT02614794 · Phase 2 · combination |
| Most frequent reported AEs | nausea 65.4% (placebo 48.5%) diarrhoea 56.7% (placebo 26.6%) fatigue 48.9% (placebo 36.5%) NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultdiarrhoea 81.7% (placebo 53.8%) palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%) nausea 60.1% (placebo 44.2%) NCT02614794 · Phase 2 · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · Tucatinib's landscape